- COMMUNITY OUTREACH AND ENGAGEMENT (COE) The Ohio State University Comprehensive Cancer Center (OSUCCC) is a national and international leader in translational research, with a reputation for delivering high-quality patient care and effective outreach and education programs to residents of the state of Ohio - our catchment area (CA) - and beyond. The CA includes all 88 counties in Ohio, which have very diverse populations, with many underserved communities as well as urban, rural and Appalachian communities. Electra Paskett, PhD, MSPH (CC) Associate Director for Population Science and Community Outreach and Director of the Center for Cancer Health Equity (CCHE) leads the Community Outreach and Engagement (COE) efforts for the OSUCCC. The CCHE is at the core of our COE efforts supporting the OSUCCC mission to reduce cancer health disparities throughout the CA. The CCHE is co- led by Darrell Gray II, MD, MPH, FACG (CC), who oversees the COE initiatives with the Clinical Trials Office to improve the accrual of women and minorities to clinical trials. COE works in the CA to connect minority populations to screening, outreach and engagement services. They also work with basic, clinical and population science program leaders in the OSUCCC to cultivate interest in CA-focused research including working with the Government Relations team and key faculty across the Center to pursue policy initiatives that address the cancer burden. COE efforts are supported by two Community Advisory Boards (rural and urban) that inform the focus and scope of CCHE activities and provide ongoing feedback to the OSUCCC leadership and Program leaders. The high priority cancers for the OSUCCC include lung, breast, colorectal, prostate, endometrial, cervical cancer, thyroid, and leukemia, as well as tobacco use, obesity and HPV vaccination. OSUCCC research and/or outreach and engagement efforts are ongoing to address these priority areas, via partnerships between the COE, OSUCCC research program members, and the community. To assess the impact of COE and OSUCCC efforts we have developed a logic model that includes short-term metrics of COE success: expanded reach (community members, patients); impact (services provided, time to diagnosis); collaborations (community partners, researchers); initiatives (grants funded); and clinical trial accrual (especially of underrepresented populations); and long-term metrics success including: reduced prevalence of risk factors and cancer rates, and longevity and impact of community partnerships. Over the last five years, we have had significant impact on HPV vaccination rates, accrual of minorities to clinical trials, breast cancer detection rates, navigation to screening and treatment, implementing translation for non-English speaking patients, fostering research to address the cancer burden in the CA. COE future plans focus on the priority cancers/risk behaviors of the OSUCCC as well as on 1) ensuring adequate communication between the community and the OSUCCC researchers as it relates to addressing the cancer burden in the catchment area and 2) a focus across the lifespan and expand to populations we are just beginning to work with (Asian, pediatric, rural clinics, LGBTQ) in order to reduce the cancer burden in our CA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10089998
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
van Oosterwijk, Jolieke G; Buelow, Daelynn R; Drenberg, Christina D et al. (2018) Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. J Clin Invest 128:369-380
Das Ghatak, Piya; Mathew-Steiner, Shomita S; Pandey, Priyanka et al. (2018) A surfactant polymer dressing potentiates antimicrobial efficacy in biofilm disruption. Sci Rep 8:873
Bhattacharya, Mohini; Berends, Evelien T M; Chan, Rita et al. (2018) Staphylococcus aureus biofilms release leukocidins to elicit extracellular trap formation and evade neutrophil-mediated killing. Proc Natl Acad Sci U S A 115:7416-7421
Kodigepalli, Karthik M; Li, Minghua; Bonifati, Serena et al. (2018) SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice. Cell Cycle 17:2564-2576
Woodard, John L; Huntsman, Andrew C; Patel, Pratiq A et al. (2018) Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones. Bioorg Med Chem 26:2354-2364
Miller, Katherine E; Kelly, Benjamin; Fitch, James et al. (2018) Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma. Cold Spring Harb Mol Case Stud 4:
Chen, Xiang; Wei, Jia; Li, Chenglong et al. (2018) Blocking interleukin-6 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells. Int J Oncol 52:571-578
Poorman, Caroline E; Ethun, Cecilia G; Postlewait, Lauren M et al. (2018) A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Ann Surg Oncol 25:520-527
Stover, Daniel G; Gil Del Alcazar, Carlos R; Brock, Jane et al. (2018) Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer 4:10
Adler, B L; Pezhouh, M K; Kim, A et al. (2018) Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med 283:568-577

Showing the most recent 10 out of 2602 publications